Science & Tech

WHO: Bundibugyo Ebola outbreak in eastern DRC worsening; deaths top 500

WHO says Bundibugyo Ebola in eastern DRC remains in an expansion phase, with 1,561 confirmed cases and over 500 deaths, straining health services.

#ebola, #drc, #who, #outbreak, #publichealth

NHS accelerates rollout of AI triage and clinician notetaking, aims for full NHS App coverage by April 2028

NHS England is fast-tracking AI triage in the NHS App for all users by April 2028 and expanding ambient voice notetaking for clinicians to cut waits and admin.

#nhs, #ai, #healthcare

MHRA grants conditional approval for Wegovy to treat MASH with fibrosis; NHS access awaits NICE review

MHRA conditionally approves Novo Nordisk’s Wegovy (semaglutide) for MASH with fibrosis; NHS availability depends on NICE appraisal and further trial data.

$NVO, #health, #pharmaceuticals, #nhs, #mash

FDA expands Casgevy gene therapy to children as young as 2 for sickle cell and beta-thalassemia

FDA clears Vertex’s Casgevy for children aged 2+ with sickle cell disease or transfusion-dependent beta-thalassemia, widening access to a one-time gene therapy.

$VRTX, #sicklecell, #gene-therapy, #casgevy, #vertex, #fda

FDA Approves Tregzi, First Regulatory T‑Cell Immunotherapy to Reduce Chronic GVHD After Donor Stem‑Cell Transplants

FDA clears Tregzi (Orca‑T), the first regulatory T‑cell immunotherapy, to lower chronic graft‑versus‑host disease after donor stem‑cell transplantation.

#fda, #celltherapy, #transplantation, #cancertreatment

450,000 New Yorkers to Lose Essential Plan Eligibility on July 1 After Federal Funding Change

About 450,000 New Yorkers with incomes 200–250% of poverty will lose $0-premium Essential Plan coverage on July 1 and must shift to marketplace plans.

#healthcare, #newyork, #essentialplan, #insurance

NHS A&E opt-out testing has identified about 1,900 previously undiagnosed HIV cases since 2022

NHS England’s opt‑out A&E blood‑borne virus testing has identified about 1,900 undiagnosed HIV cases since April 2022; independent analysis and funding back the scheme.

#hiv, #nhs, #publichealth, #testing

FDA Expands IBRANCE Approval for Maintenance Treatment in HR+, HER2+ Metastatic Breast Cancer

FDA expands use of Pfizer’s IBRANCE (palbociclib) as maintenance therapy with trastuzumab and endocrine therapy for HR+, HER2+ metastatic breast cancer.

$PFE, #oncology, #breastcancer, #fda, #pharma

Open-source AI improved doctors' rare-disease diagnoses in trial — but increased high-confidence errors

Preprint: open-source model RaDaR raised physicians’ rare-disease diagnostic accuracy by 21.4 points in a randomized case-based trial — but produced more high-confidence errors.

#ai, #raredisease, #diagnosis, #medicalai

Millions Lose Marketplace Coverage and Pay More After Boosted ACA Subsidies Lapse

Six months after enhanced ACA subsidies ended, enrollment and payment data show millions lost coverage and many who kept plans face much higher costs.

#healthcare, #aca, #insurance, #enrollment

Pfizer’s Phase 3 Lung Cancer Drug Misses Overall Survival Goal; Stronger Trend in Second‑Line Patients

Pfizer's Phase 3 lung cancer trial of sigvotatug vedotin missed its overall survival goal; company sees a stronger trend in second‑line patients.

$PFE, #pfizer, #oncology, #lungcancer, #clinicaltrials

Final UN/EU/World Bank RDNA: Gaza’s health system needs $10.03 billion to rebuild; 14% of workforce lost

A joint UN/EU/World Bank assessment estimates $10.03B needed over five years to rebuild Gaza’s health system and reports 14% of health workers lost.

#gaza, #healthcare, #un, #worldbank

NHS data shows UK-trained and prioritised applicants filled 98% of 2026 specialty training posts

NHS England: 98% of 2026 specialty training posts went to UK graduates or other priority groups after the new prioritisation law took effect.

#nhs, #medical-training, #prioritisation, #uk-health

Intellia’s one-time CRISPR therapy cuts hereditary angioedema attacks 87% in Phase 3; rolling FDA filing started

Phase 3 trial of Intellia's one-time in‑vivo CRISPR therapy lonvo‑z cut hereditary angioedema attacks 87%; company began rolling FDA filing.

$NTLA, #crispr, #geneediting, #biotech, #hereditaryangioedema, #intellia

UK to spend nearly £30m to expand AI diagnostics in the NHS; £20m to roll out chest X‑ray tools to trusts by 2029

UK to invest almost £30m to expand AI-assisted diagnostics in the NHS, including £20m to roll out AI chest X-ray tools to all English trusts by 2029.

#nhs, #ai, #healthcare, #lungcancer